skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

28 Total results for product and free and sample content found

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Biomedtracker

Q2 Outlook Report Extract

10 May 2018

Get a reliable and accurate view of what’s on the horizon for pharma in the coming quarter. The Biomedtracker Q2 2018 Outlook Report includes essential information, including each drug’s likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.

Topic Drug review

Biomedtracker

Biomedtracker 2018 Early Outlook Report

03 May 2018

What's on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

Topic Drug development landscape

Biomedtracker

BMT Q4 Outlook Report

27 Oct 2017

In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimers Cancer Drug approval

Pharmaprojects

Building something great: UK's Global Bioscience Cluster 2016

10 Oct 2017

The UK has some of the world’s most exciting science, a supportive business environment, and strong companies led by experienced management teams.

Topic BioPharmaceutical

Medtrack

Partnering in the Pharma World

25 Sep 2017

The 23rd Annual International Partnering Conference, Bio Europe 2017, November 6 – 8, in Berlin, Germany is fast approaching. Via one-on-one partnering meetings, attendees over the world from all facets of biotech will meet at Europe’s largest life science partnering conference to identify, engage with, and enter into strategic relationships to drive their business forward.

Topic Clinical trials

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Medtrack

Maximizing Royalty Rate Opportunities in Pharma Licensing

By Steven Muntner 16 Sep 2017

Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles.

Topic Deal trends Medtech

Datamonitor Healthcare

Big Pharma Outlook 2026 Pharmavitae Analytics Report Extract

05 Aug 2017

Big Pharma Outlook 2026 takes decade-long look at what’s in store for the future of Big Pharma.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: